Biomea Fusion, Inc.
Close on Oct 19, 2026
- Market cap
- $60.46M
- P/E (TTM)
- –
- Dividend yield
- –
About Biomea Fusion
Pharmaceutical Preparations, SIC 2834
Biomea Fusion is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule therapies for metabolic conditions. The organization focuses on treatments for type 1 diabetes, type 2 diabetes, and obesity. Its research pipeline centers on two core investigational programs: icovamenib, an oral covalent menin inhibitor under study for diabetes and obesity, and BMF-650, an oral glucagon-like peptide-1 receptor agonist in development for obesity. The company has no commercialized products, and its investigational therapies target patient populations suffering from diabetes and metabolic disorders.
The company is headquartered in San Carlos, California, where it maintains its principal executive offices. Its workforce consists of approximately 40 employees who support research, clinical development, clinical operations, clinical pharmacology, regulatory affairs, pharmacovigilance, and quality functions. The company operates within the United States, and the provided report identifies no additional operating facilities, stores, or international offices.
Summary of the business section of Biomea Fusion's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Biomea Fusion, Inc.
- Founded
- 2017
- Headquarters
- San Carlos, CA
- Address
- 1599 Industrial Road 94070
- Phone
- (650) 980-9099
- Website
- biomeafusion.com
- Employees
- 41, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, CA
Stock & identifiers
- Ticker
- BMEA
- Exchange
- Nasdaq
- IPO date
- Apr 19, 2021
- Shares outstanding
- 72M, Jul 31, 2026
- Public float
- $93.61M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1840439
- CUSIP
- 09077A106
- ISIN
- US09077A1060
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael J.M. Hitchcock | Interim CEO, Director | 115,000 |
| Rainer M. Erdtmann | See Remarks, Director | 987,041 |
| Franco Valle | Chief Financial Officer | 42,995 |
| Julianne Averill | Director | – |
| Eric Aguiar | Director | – |
| Elizabeth Faust | Director | – |
| Sumita Ray | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 41 full-time employees, 27 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 27, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 19, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |